M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
about
Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogsTrafficking regulation of proteins in Alzheimer's diseaseAllosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent mannerCholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity.Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors.Hippocampal M1 receptor function associated with spatial learning and memory in aged female rhesus macaques.Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderAge-associated learning and memory deficits in two mouse versions of the Stone T-maze.Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?Role of melatonin in Alzheimer-like neurodegeneration.Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.Donepezil: a review.Inactivation of JAK2/STAT3 signaling axis and downregulation of M1 mAChR cause cognitive impairment in klotho mutant mice, a genetic model of agingMelatonin in Alzheimer's diseaseThe PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events.Current and future therapy in Alzheimer's disease.Current therapeutic targets for the treatment of Alzheimer's disease.Current perspectives on pharmacotherapy of Alzheimer's disease.In vitro safety pharmacology profiling: what else beyond hERG?Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's DiseaseNovel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.Progress in the development of new drugs in Alzheimer's disease.Deficit in learning and memory of rats with chronic fluorosis correlates with the decreased expressions of M1 and M3 muscarinic acetylcholine receptors.Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor.Population-based study suggests an increased risk of Alzheimer'sdisease in Sjögren's syndrome.Interpreting the structural mechanism of action for MT7 and human muscarinic acetylcholine receptor 1 complex by modeling protein-protein interaction.Pharmacological effects of Ibuprofen on learning and memory, muscarinic receptors gene expression and APP isoforms level in pre-frontal cortex of AlCl₃-induced toxicity mouse model.Muscarinic receptor dependent long-term depression in rat visual cortex is PKC independent but requires ERK1/2 activation and protein synthesis.A Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy.L-Satropane Prevents Retinal Neuron Damage by Attenuating Cell Apoptosis and Aβ Production via Activation of M1 Muscarinic Acetylcholine Receptor.High-energy compounds promote physiological processing of Alzheimer's amyloid-β precursor protein and boost cell survival in culture.M1 muscarinic acetylcholine receptor agonism alters sleep without affecting memory consolidation.Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative.The snake venom peptide Bj-PRO-7a is a M1 muscarinic acetylcholine receptor agonist.Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.
P2860
Q24635261-1BDB6229-FD60-420F-A42C-49E84E11C906Q26825722-2E55D0AF-B498-4662-8ABA-759C638EE1D8Q30388923-BF91D31E-530F-45A8-8F5D-774D8074B647Q30530935-358BEA14-1202-4BD7-8FDB-69D4D446A635Q33927277-8FD46025-B46A-4BB8-9095-EECD234756F2Q33998388-0F506DA4-D1A5-41C4-A563-7EB4E6CD235AQ34104256-BEB5A3F8-8D9C-42D6-A697-7232A40DB977Q34438832-EB44ACC4-5DC4-4C2F-898B-6CB1E43F0A7EQ34552778-C1491A56-E86B-45FF-9CB5-1C22BD8F446FQ35103820-DA89BA4A-F67D-4085-8FB0-768595F82A7BQ35201147-8F5A33DF-3059-4CAB-9CF4-0FA59382FD65Q35546189-5BFDC92B-D53C-4ED9-B230-954F3D0E729AQ35875514-210648F5-6768-41F2-8154-8417B4F12A4EQ36302845-A7F2154B-FBAB-4D64-8091-3C29B1CD2C07Q36346522-E7EA2DC2-43EF-4506-B260-65CBE1CB1D0EQ36401406-D82F41C9-F960-4677-A1CF-613FED23F909Q36544994-2C5330E5-8531-46CB-85F2-DFF227F5CE66Q36927714-F211A0EE-2AF7-4834-910C-956F9A0AFAD9Q37091982-72CF8F09-5EC1-4F35-BBFF-C2E4688D470BQ37145922-C4B01784-DB27-4C69-A5B5-BAABCAD78CE7Q37165703-227AAE71-B633-4FD7-B90F-BF563EC85754Q37737296-C427ABBC-1A2D-46F0-8001-3E46FDDC6860Q37827489-F866AA0F-7CAD-4C96-98BF-7AAA69762BD8Q37855844-B342D660-3AB2-4E21-B256-9E6125E7789CQ38788038-ED66ACE0-9026-4F02-AB2F-1926D538FCEBQ39155961-0E537004-BC6E-4117-849F-4314464D1E33Q39789745-826D6E75-647B-4522-96F4-38008FD2C0BCQ42703574-6F92EFC4-8AE2-4C6C-9946-BD368B14F8C1Q46822777-BF9C3F78-0468-4206-8430-546BBB84E2E5Q47306169-D4DF6CE7-BE72-49B0-ABA3-979EB1F79689Q47788379-C59E0E86-1BD1-4659-9EE4-94D52CEBF2EDQ47876298-AA02E031-08D7-404C-969E-02BD5151B53EQ48103250-CB03539B-2E10-4EC0-9042-612CDEF0315FQ48136609-0714AFEF-ADE9-42E5-9D46-7C9F42A54D0CQ48250501-87C66D46-FA76-495A-B19E-1D3DF13C3090Q48404424-3A43E546-E5DF-4DFD-A707-695B5E7DBB21Q48486682-7D1D7996-DF52-4C88-840C-856268171590Q51037995-67180FAF-D4C4-4248-8D97-63F3B4CC5335Q51771947-FDCBAF17-BF01-4C8A-8C6D-8B300192CCE0Q55405667-7C156A8D-14F6-4640-A06D-FCB6D0CC7AA3
P2860
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
M1 muscarinic agonists can mod ...... mplications in future therapy.
@ast
M1 muscarinic agonists can mod ...... mplications in future therapy.
@en
type
label
M1 muscarinic agonists can mod ...... mplications in future therapy.
@ast
M1 muscarinic agonists can mod ...... mplications in future therapy.
@en
prefLabel
M1 muscarinic agonists can mod ...... mplications in future therapy.
@ast
M1 muscarinic agonists can mod ...... mplications in future therapy.
@en
P2093
P356
P1476
M1 muscarinic agonists can mod ...... mplications in future therapy.
@en
P2093
Abraham Fisher
Hagar Sonego
Inbal Egozi
Itzhak Marcovitch
Michal Kliger-Spatz
Nira Bar-Ner
Niva Natan
Rachel Brandeis
Rachel Haring
Zipora Pittel
P2888
P304
P356
10.1385/JMN:20:3:349
P577
2003-01-01T00:00:00Z
P6179
1026532374